View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
April 7, 2022

Yescarta’s new label expansion opens the door to B-NHL dominance

Yescarta is the only CAR-T therapy approved for second-line treatment of relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma.

By GlobalData Healthcare

Patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (B-NHL), including diffuse large B-cell lymphoma (DLBCL), have three chimeric antigen receptor T (CAR-T) therapy options available in the R/R setting. The US Food and Drug Administration (FDA) approved a label expansion for Gilead’s Yescarta (axicabtagene ciloleucel) this month, making it the only CAR-T therapy approved for use in the second line of therapy. Yescarta and its competitors, Novartis’ Kymriah (tisagenlecleucel) and Bristol-Myers Squibb’s (BMS) Breyanzi (lisocabtagene maraleucel), are all CD19 antigen-targeting autologous modified CAR-T cells. While sales for Kymriah and Yescarta have shown that the B-NHL space can support at least two competing CAR-T products, the fate of the latecomer Breyanzi is less certain, and further threatened by Yescarta’s recent move into the second line.

Yescarta’s FDA label expansion was based on results from the Phase III ZUMA-7 randomised trial, which enrolled 359 eligible patients who had received at least one prior line of therapy and were either primarily refractory or relapsed within 12 months. The control arm included best available standard-of-care chemotherapy regimens with or without stem cell transplant. At the time of data cut-off, the overall event-free survival was 8.3 months for Yescarta versus only two months for the control arm. The overall response rate was 83% with Yescarta versus 50% for the control. Typical side effects of CAR-T cells include cytokine release syndrome (CRS) and neurotoxicity. Yescarta led to 7% of patients experiencing Grade III or higher CRS and 25% of patients experiencing Grade III or higher neurologic events, which is substantial, but unlikely to hinder clinical uptake given similar rates of neurotoxicity among all current CAR-T products.

While high clinical uptake is expected in the third line and upwards for all agents, a move into the earlier lines of therapy can lead to very high revenues in B-NHL and rapidly change the competitive dynamics. By moving into the second line, Gilead has essentially doubled the number of patients eligible to receive Yescarta, and this can give it the upper hand in this disease. BMS has also submitted a supplemental biologics license application to the FDA for Breyanzi in the second line, with a response expected by June this year. Because of this, Yescarta might enjoy a competition-free environment in the second line for a few months, which may prove enough to inspire physician confidence and lead to higher uptake over Breyanzi.

Yescarta’s first-mover advantage has so far translated to higher sales than Kymriah. Specifically, the drug reported sales of $706m last year, compared with $587m for Kymriah (which, however, also includes sales in acute lymphocytic leukaemia) and $87m for Breyanzi. GlobalData’s analyst consensus forecasts place Yescarta at $1.5bn in peak sales, and with the current label expansion in the second line, this figure can be achieved within the next four years.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy